IL-I gene polymorphism and smoking as risk factors for peri-implant bone loss in a well-maintained population
IL-I gene polymorphism and smoking as risk factors for peri-implant bone loss in a well-maintained population
复制标题
DOI：
10.1034/j.1600-0501.2003.140102.x
复制
发表时间：
2003-02-01
影响因子：
4.3
通讯作者：
Kornman, KS
中科院分区：
文献类型：
--
作者：
Feloutzis, A;Lang, NP;Kornman, KS
本研究的目的是(I)在吸烟者和不吸烟者中，研究特定的白介素1(IL-1)基因多态性与种植体周围骨丢失的关系，以及(Ii)在吸烟者和非吸烟者中，IL-1基因复合体的这些等位基因变异与种植体周黏膜炎症之间的关系。一个连续的90名高加索患者(年龄33-88岁)的样本，接受了至少一种ITI-种植体的治疗，参与了这项回顾调查。在假体修复后(133.6天，SD 136.9天)和复查时拍摄标准化的根尖周片，平均5.6年(SID 2.5年)。放射片由校准的检查员分析种植体周围骨水平的变化。检查员在临床参数和IL-1状态方面是盲人。在各个时间点用计算机方法测量种植体肩部与第一次可见的骨-种植体接触(DIB)之间的距离。计算所有种植体的服务年限内的绝对骨水平差(ABL)和年骨丢失(ABL/年)。对所有就诊患者的探诊时全口出血百分比(BOP)以及牙齿和种植体分别计算的BOP百分比进行测定，并在整个观察期内取平均值。在总的患者样本中，有14名重度吸烟者(=20支/天)，14名中度吸烟者(每天5-19支)，23名既往吸烟者(戒烟5年)和39名不吸烟者。IL-1基因阳性28例(31.11%)。对吸烟状况进行分层后，IL-1基因阳性组的非吸烟者和重度吸烟者的ABL(P<；0.04，U检验)和DeltaBL/Year(P<；0.04，U检验)差异有统计学意义，而IL-1基因阴性组的ABL(P<；0.04，U检验)差异无统计学意义。此外，在IL-1基因阳性组中，既往吸烟者与重度吸烟者的ABL(P<；0.04，U-检验)和ABL/Year(P<；0.04，U-检验)有显著差异。炎症参数(BOP)差异无统计学意义。这项研究表明，在重度吸烟者中，携带具有显著功能意义的IL-1基因复合体多态性与假体重建后和治疗的支持性牙周护理阶段种植体周围骨丢失的风险增加有关。
The aim of the present study was (i) to investigate the relation between specific interleukin-1 (IL-1) gene polymorphisms and peri-implant bone loss at osseointegrated ITI(R) dental implants and (ii) to explore the association between these allelic variants of the IL-1 gene complex and peri-implant mucosal inflammation, in both smoking and non-smoking individuals. A sample of 90 consecutive Caucasian patients (aged 33-88 years), treated with at least one ITI-implant participated in this retrospective investigation. Standardized periapical radiographs were taken after prosthetic rehabilitation (133.6 days, SD 136.9 days) and at the time of the re-examination, on average 5.6 years (SID 2.5 years) thereafter. The radiographs were analyzed by a calibrated examiner for changes in peri-implant bone levels. The examiner was blind with respect to clinical parameters and IL-1 status. The distance between the implant shoulder and the first visible bone-implant contact (DIB) at the respective time points were measured using a computerized method. The absolute bone level difference during the years of service (ABL) and the annual bone loss (ABL/year) were calculated for all the implants. Percentages of full mouth bleeding on probing (BOP), as well as of BOP calculated separately for teeth and implants, were determined for all visits and averaged for the entire observation period. Out of the total patient sample, there were 14 heavy smokers (= 20 cigarettes/day), 14 moderate smokers (5-19 cigarettestday), 23 previous smokers (smoking cessation > 5 years) and 39 non-smokers. Twenty-eight (31.11 %) patients were IL-1 genotype positive. Upon stratification for smoking status, significant differences were found for the variables ABL (P < 0.04, U-test) and DeltaBL/year (P < 0.04, U-test) between non-smokers and heavy smokers for the IL-1 genotype positive group but not for the IL-1 genotype negative group. Moreover, significant differences in ABL (P < 0.04, U-test) and ABL/year (P < 0.04, U-test) were identified between former smokers and heavy smokers for the IL-1 genotype positive group. The differences in inflammatory parameters (BOP) did not reach statistical significance. This study suggests that in heavy cigarette smokers, carriage of a functionally significant IL-1 gene complex polymorphism is associated with an increased risk for peri-implant bone loss following prosthetic reconstruction and during the supportive periodontal care phase of the treatment.